UNIVERSITY OF MIAMI

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1925-01-01

Employees: 10K

Market Cap: -

Website: https://continue.miami.edu/packagedetail.aspx

Clinical Trials

Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer

Phase 1

Withdrawn

Conditions: Cervical Cancer

First Posted Date: 2007-03-28

Last Posted Date: 2016-12-15

Lead Sponsor: University of Miami

Registration Number: NCT00452920

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract

Phase 2

Completed

Conditions: Head and Neck Cancer
Precancerous/Nonmalignant Condition

Interventions: Drug: Porfimer Sodium
Procedure: Photodynamic Therapy

First Posted Date: 2007-03-28

Last Posted Date: 2017-02-08

Lead Sponsor: University of Miami

Target Recruit Count: 45

Registration Number: NCT00453336

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Phase 2

Completed

Conditions: Marginal Zone Lymphoma

Interventions: Drug: Rituximab
Drug: Ibritumomab Tiuxetan

First Posted Date: 2007-03-28

Last Posted Date: 2016-01-01

Lead Sponsor: University of Miami

Target Recruit Count: 18

Registration Number: NCT00453102

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery

Phase 1

Completed

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone
Sarcoma

Interventions: Drug: celecoxib
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2007-03-22

Last Posted Date: 2016-12-15

Lead Sponsor: University of Miami

Target Recruit Count: 3

Registration Number: NCT00450736

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2007-03-22

Last Posted Date: 2017-06-23

Lead Sponsor: University of Miami

Target Recruit Count: 57

Registration Number: NCT00450385

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
University of Rochester Medical Center - Wilmot Cancer Institute, Rochester, New York, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 2 locations

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Isosulfan blue
Procedure: Axillary Lymph Node Dissection
Procedure: Surgery
Procedure: Sentinel Lymph Node Biopsy
Procedure: Thoracoscopic Surgery
Radiation: Technetium Tc 99m Sulfur Colloid

First Posted Date: 2007-03-22

Last Posted Date: 2017-02-07

Lead Sponsor: University of Miami

Target Recruit Count: 39

Registration Number: NCT00450723

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: ADI-PEG-20
Other: Pharmacology Studies

First Posted Date: 2007-03-22

Last Posted Date: 2017-02-08

Lead Sponsor: University of Miami

Target Recruit Count: 38

Registration Number: NCT00450372

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Doxorubicin
Drug: Etoposide
Drug: Ifosfamide
Drug: Leucovorin
Drug: Methotrexate
Drug: Thalidomide
Drug: Vincristine
Drug: Mesna
Drug: Filgrastim (G-CSF)
Drug: Granisetron
Drug: Decadron

First Posted Date: 2007-03-22

Last Posted Date: 2015-11-10

Lead Sponsor: University of Miami

Target Recruit Count: 22

Registration Number: NCT00450801

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Not Applicable

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2007-03-19

Last Posted Date: 2016-12-15

Lead Sponsor: University of Miami

Target Recruit Count: 42

Registration Number: NCT00448838

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Docetaxel
Drug: Floxuridine
Drug: Leucovorin
Drug: Oxaliplatin
Genetic: Microarray analysis
Genetic: reverse transcriptase-polymerase chain reaction
Procedure: Conventional surgery

First Posted Date: 2007-03-19

Last Posted Date: 2017-02-07

Lead Sponsor: University of Miami

Target Recruit Count: 29

Registration Number: NCT00448760

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy